📊 PRLD Key Takeaways
Is Prelude Therapeutics Inc (PRLD) a Good Investment?
Prelude Therapeutics exhibits unsustainable financial fundamentals with critical cash runway of <12 months at current burn rates. With operating cash flow of -21.7M against only 21.8M cash reserves and revenue of 4.6M, the company faces urgent near-term financing needs that create significant downside risk.
Prelude Therapeutics Inc Key Strengths (PRLD)
- Revenue growth of 73.4% YoY demonstrates emerging commercial traction despite small base
- Zero debt with positive stockholders equity of 60.2M provides clean balance sheet
- Current and quick ratios of 2.03x indicate adequate near-term liquidity for operations
PRLD Stock Risks: Prelude Therapeutics Inc Investment Risks
- Cash runway of approximately 12 months at current 21.7M annual operating burn rate requires imminent financing
- Operating loss of 14.2M on 4.6M revenue demonstrates severe unit economics and unprofitability
- Operating margin of -309% and net margin of -227% indicate business model is fundamentally challenged
Key Metrics to Watch
- Path to operating cash flow breakeven and burn rate reduction trajectory
- Revenue growth sustainability and achievement of positive gross margins on commercial products
- Cash position, financing announcements, and dilution from equity raises
Prelude Therapeutics Inc (PRLD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.03x current ratio provides a solid financial cushion.
PRLD Profit Margin, ROE & Profitability Analysis
PRLD vs Healthcare Sector: How Prelude Therapeutics Inc Compares
How Prelude Therapeutics Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Prelude Therapeutics Inc Stock Overvalued? PRLD Valuation Analysis 2026
Based on fundamental analysis, Prelude Therapeutics Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Prelude Therapeutics Inc Balance Sheet: PRLD Debt, Cash & Liquidity
PRLD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Prelude Therapeutics Inc's revenue has grown significantly by 73% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.68 indicates the company is currently unprofitable.
PRLD Revenue Growth, EPS Growth & YoY Performance
PRLD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$10.4M | $-0.13 |
| Q3 2025 | $3.0M | -$19.7M | $-0.26 |
| Q3 2024 | $3.0M | -$27.7M | $-0.43 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Prelude Therapeutics Inc Dividends, Buybacks & Capital Allocation
PRLD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Prelude Therapeutics Inc (CIK: 0001678660)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PRLD
What is the AI rating for PRLD?
Prelude Therapeutics Inc (PRLD) has an AI grade of D with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PRLD's key strengths?
Claude: Revenue growth of 73.4% YoY demonstrates emerging commercial traction despite small base. Zero debt with positive stockholders equity of 60.2M provides clean balance sheet.
What are the risks of investing in PRLD?
Claude: Cash runway of approximately 12 months at current 21.7M annual operating burn rate requires imminent financing. Operating loss of 14.2M on 4.6M revenue demonstrates severe unit economics and unprofitability.
What is PRLD's revenue and growth?
Prelude Therapeutics Inc reported revenue of $4.6M.
Does PRLD pay dividends?
Prelude Therapeutics Inc does not currently pay dividends.
Where can I find PRLD SEC filings?
Official SEC filings for Prelude Therapeutics Inc (CIK: 0001678660) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PRLD's EPS?
Prelude Therapeutics Inc has a diluted EPS of $-0.13.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PRLD's fundamental grade?
Based on our AI fundamental analysis in June 2026, Prelude Therapeutics Inc has a D grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PRLD stock overvalued or undervalued?
Valuation metrics for PRLD: ROE of -17.3% (sector avg: 15%), net margin of -226.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PRLD's AI grade for 2026?
Our dual AI analysis gives Prelude Therapeutics Inc a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PRLD's free cash flow?
Prelude Therapeutics Inc's operating cash flow is $-21.7M, with capital expenditures of $0.0. FCF margin is -473.5%.
How does PRLD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -226.7% (avg: 12%), ROE -17.3% (avg: 15%), current ratio 2.03 (avg: 2).